1. Kadmon Holdings. FDA grants orphan drug designation to Kadmon's KD025 for the treatment of cGVHD [media release]. 6 Oct 2017. http://www.kadmon.com.
2. Kadmon Holdings. FDA grants breakthrough therapy designation to Kadmon's KD025 for chronic graft-versus-host disease [media release]. 17 Oct 2018. http://www.kadmon.com.
3. Kadmon Holdings. Kadmon announces FDA acceptance of NDA for belumosudil in patients with chronic graft-versus-host disease [media release]. 30 Nov 2020. http://www.kadmon.com.
4. US FDA. REZUROCK™ (belumosudil) tablets, for oral use: US prescribing information. 2021. https://www.accessdata.fda.gov. Accessed 18 Aug 2021.
5. Kadmon Pharmaceuticals. US FDA grants full approval of REZUROCK™ (belumosudil) for the treatment of patients with chronic graft-versus-host disease (cGVHD) [media release]. 16 Jul 2021. https://investors.kadmon.com.